A $46M Bet on a New Way to Treat the Most Common Genetic Kidney Disease

Jan de Vries · 2026-08-07

A small biotech in Glasgow just landed a massive vote of confidence. Mironid has closed a $46 million Series B round to push its lead drug candidate through clinical development for Autosomal Dominant Polycystic Kidney Disease, or ADPKD. That's a big deal for the roughly 12 million people worldwide living with this condition. ### Why This Funding Round Matters The round was led by the Scottish National Investment Bank, with existing backers like the Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, and the University of Strathclyde all chipping in again. When that many sophisticated investors double down, it's worth paying attention. Neil Wilkie, Mironid's CEO, put it plainly: "ADPKD is the most common hereditary kidney disorder, affecting over 12 million people worldwide, with 50% of patients developing kidney failure by the age of 60." He added, "Securing funding from such a high-calibre syndicate is a strong validator of our approach." The fresh capital will fund the clinical development of Mironid's lead compound, a first-in-class small molecule designed to tackle ADPKD at its root. For patients, that could mean a real alternative to the current standard of care. ### The Science Behind the Approach ADPKD is caused by mutations in the PKD1 or PKD2 genes. Those mutations lead to uncontrolled growth of fluid-filled cysts in the kidneys. Over time, the cysts crowd out healthy tissue, and roughly half of patients end up with kidney failure by age 60. Mironid's LoAc molecules take a different tack. Instead of just managing symptoms, they directly target cyclic AMP (cAMP), a cellular signal that drives both cell proliferation and fluid secretion inside the cysts. The company says this signal is active at every stage of the disease, from the very beginning all the way to end-stage. Preclinical data looks promising. Studies showed significant reductions in cyst number and kidney volume, along with a favorable safety profile. By preventing new cysts from forming and stopping existing ones from growing, this approach could offer a more durable treatment with fewer side effects compared to what's out there now. ### More Than Just One Drug Mironid isn't a one-trick pony. Beyond ADPKD, the pipeline targets phosphodiesterase 4 (PDE4) enzymes, which play a key role in cell signaling pathways tied to disease progression. The company also has its eye on major inflammatory diseases and cancer. Spun out of the University of Strathclyde and Heriot-Watt University in 2015, Mironid builds on over three decades of research into PDE biology by Professor Miles Houslay. The company is headquartered in Glasgow and operates on a research-and-development-led model, funded through venture capital and strategic investment. Paul Callaghan, Investment Director at the Scottish National Investment Bank, summed up the sentiment: "Mironid exemplifies Scotland's growing reputation for biotech innovation, developing a new treatment approach that could improve options for people living with kidney disease." This Series B follows an earlier Series A extension that brought Mironid's total funding since inception to roughly $47 million. That war chest gives the company runway to keep pushing its lead candidate through the clinic and, hopefully, toward commercialization. For the biotech world, this is another sign that rare disease research is attracting serious capital. For patients, it's a glimmer of hope that a better treatment might be on the horizon. Either way, Mironid is one to watch.